Antigen Information

General Information of This Antigen (ID: TAR0NEZUA)
Antigen Name
Mesothelin (MSLN)
Gene Name
MSLN
Gene ID
10232
Synonym
MPF; CAK1 antigen;Pre-pro-megakaryocyte-potentiating factor
Sequence
MALP.PLLGSCGTPALGSLLFLLFSLGWVQPSRTLAGETGQEAAPLDGVLANPPNISSLS
PRQLLGFPCAEVSGLSTERVRELAVALAQKNVKLSTEQLRCLAHRLSEPPEDLDALPLDL
LLFLNPDAFSGPQACTRFFSRITKANVDLLPRGAPERQRLLPAALACWGVRGSLLSEADV
RALGGLACDLPGRFVAESAEVLLPRLVSCPGPLDQDQQEAARAALQGGGPPYGPPSTWSV
STMDALRGLLPVLGQPIIRSIPQGIVAAWRQRSSRDPSWRQPERTILRPRFRREVEKTAC
PSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELYPQ
GYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQAPRRPLPQVATL
IDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQLD
VLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVLPL
TVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTLGLGLQGGIPNGYLVLDLSMQ
EALSGTPCLLGPGPVLTVLALLLASTLA

    Click to Show/Hide
Family
LAMP family
Function
Membrane-anchored forms may play a role in cellular adhesion.; Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.

    Click to Show/Hide
Uniprot Entry
MSLN_HUMAN
HGNC ID
HGNC:7371
KEGG ID
hsa:10232
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
ADC Name Payload Target Linker ADC Info
WO2024105205A1 1m-107 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
ADC Name Payload Target Linker ADC Info
WO2024105205A1 1m-107* [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
ADC Name Payload Target Linker ADC Info
WO2024105205A1 2m-170 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 3m-170 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 4m-170 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 5m-170 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 6m-170 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 7m-170 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 8m-170 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 11m-170a [1]
KSPI6-1
Undisclosed
WO2024105205A1-11m-170a-Linker
 ADC Info 
WO2024105205A1 11m-170a* [1]
KSPI6-1
Undisclosed
WO2024105205A1-11m-170a-Linker
 ADC Info 
WO2024105205A1 11m-170b [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 12m-170a 1 [1]
KSPI6-1
Undisclosed
WO2024105205A1-12m-170a-Linker
 ADC Info 
WO2024105205A1 12m-170a 2 [1]
KSPI6-1
Undisclosed
WO2024105205A1-12m-170a-Linker
 ADC Info 
WO2024105205A1 13m-170 [1]
KSPI6-1
Undisclosed
Undisclosed
 ADC Info 
WO2024105205A1 14m-170 [1]
KSPI6-1
Undisclosed
WO2024105205A1-14m-170-Linker
 ADC Info 
Amatuximab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
MSLN-Mal-PEG2-Val-Cit-PABC-Eribulin [2]
Eribulin
Microtubule (MT)
Mal-PEG2-Val-Cit-PABC
 ADC Info 
MSLN-Mal-PEG8-Val-Cit-PABC-Eribulin [2]
Eribulin
Microtubule (MT)
Mal-PEG8-Val-Cit-PABC
 ADC Info 
MSLN-Mal-Caproyl-Val-Cit-PABC-Eribulin [2]
Eribulin
Microtubule (MT)
Maleimide-Caproyl-Val-Cit-PABC
 ADC Info 
MSLN-Mal-PEG2-Ala-Ala-Asn-PABC-Eribulin [2]
Eribulin
Microtubule (MT)
Mal-PEG2-Ala-Ala-Asn-PABC
 ADC Info 
MSLN-Mal-PEG4-tria-PEG3-Dis-dim-PABC-Eribulin [2]
Eribulin
Microtubule (MT)
Mal-PEG4-triazole-PEG3-Disulfidyl-dimethyl-PABC
 ADC Info 
MSLN-Mal-PEG4-tria-PEG3-Sulfo-Eribulin [2]
Eribulin
Microtubule (MT)
Mal-PEG4-triazole-PEG3-Sulfonamide
 ADC Info 
MSLN-Mal-PEG2-Eribulin [2]
Eribulin
Microtubule (MT)
Mal-PEG2
 ADC Info 
MSLN-Mal-PEG4-Eribulin [2]
Eribulin
Microtubule (MT)
Mal-PEG4
 ADC Info 
MSLN-Suc/SPAAC-PEG4-Val-Cit-PABC-Eribulin [2]
Eribulin
Microtubule (MT)
Succinamide-SPAAC-PEG4-Val-Cit-PABC
 ADC Info 
MSLN-Suc/SPAAC-PEG3-Dis-dim-PABC-Eribulin [2]
Eribulin
Microtubule (MT)
Succinamide-SPAAC-PEG3-Disylfidyl-dimethyl-PABC
 ADC Info 
MSLN-Suc/SPAAC-PEG3-Sulfonamide-Eribulin [2]
Eribulin
Microtubule (MT)
Succinamide-SPAAC-PEG3-Sulfonamide
 ADC Info 
MSLN-Suc/SPAAC-PEG2-Eribulin [2]
Eribulin
Microtubule (MT)
Succinamide-SPAAC-PEG2
 ADC Info 
MSLN-Suc/SPAAC-PEG4-Eribulin [2]
Eribulin
Microtubule (MT)
Succinamide-SPAAC-PEG4
 ADC Info 
MSLN-Mal-PEG-Val-Cit-PABC-Cryptophycin [2]
Cryptophycin
Microtubule (MT)
Mal-PEG-Val-Cit-PABC
 ADC Info 
MSLN-Mal-Caproyl-Val-Cit-PABC-MMAE [2]
Monomethyl auristatin E
Microtubule (MT)
Maleimide-Caproyl-Val-Cit-PABC
 ADC Info 
MSLN-Mal-Caproyl-Val-Cit-PABC-MMAF [2]
Monomethyl auristatin F
Microtubule (MT)
Maleimide-Caproyl-Val-Cit-PABC
 ADC Info 
Amatuximab-Compound 9 [3]
Mertansine DM1
Microtubule (MT)
Amatuximab-Compound 9 linker
 ADC Info 
Amatuximab-Compound 17 [3]
Mertansine DM4
Microtubule (MT)
Amatuximab-Compound 17 linker
 ADC Info 
Amatuximab-Compound 25 [3]
Monomethyl auristatin E
Microtubule (MT)
Amatuximab-Compound 25 linker
 ADC Info 
Amatuximab-Compound 31 [3]
Auristatin 0101
Microtubule (MT)
Amatuximab-Compound 31 linker
 ADC Info 
Amatuximab-Compound 36 [3]
Monomethyl auristatin E
Microtubule (MT)
Amatuximab-Compound 36 linker
 ADC Info 
Amatuximab-Compound 43 [3]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Amatuximab-Compound 43 linker
 ADC Info 
Amatuximab-Compound 49 [3]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Amatuximab-Compound 49 linker
 ADC Info 
Amatuximab-Compound 55 [3]
Mertansine DM1
Microtubule (MT)
Amatuximab-Compound 55 linker
 ADC Info 
Amatuximab-Compound 59 [3]
Mertansine DM4
Microtubule (MT)
Amatuximab-Compound 59 linker
 ADC Info 
Amatuximab-Compound 64 [3]
Monomethyl auristatin E
Microtubule (MT)
Amatuximab-Compound 64 linker
 ADC Info 
Amatuximab-Compound 69 [3]
Monomethyl auristatin E
Microtubule (MT)
Amatuximab-Compound 69 linker
 ADC Info 
Amatuximab-Compound 74 [3]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Amatuximab-Compound 74 linker
 ADC Info 
Amatuximab-Compound 75 [3]
Monomethyl auristatin E
Microtubule (MT)
Amatuximab-Compound 75 linker
 ADC Info 
Amatuximab-Compound 76 [3]
Monomethyl auristatin E
Microtubule (MT)
Amatuximab-Compound 76 linker
 ADC Info 
Amatuximab-Compound 77 [3]
Mertansine DM1
Microtubule (MT)
Amatuximab-Compound 77 linker
 ADC Info 
Amatuximab-Compound 78 [3]
Auristatin 0101
Microtubule (MT)
Amatuximab-Compound 78 linker
 ADC Info 
Amatuximab-Compound 79 [3]
Auristatin 0101
Microtubule (MT)
Amatuximab-Compound 79 linker
 ADC Info 
Amatuximab-Compound 80 [3]
Mertansine DM4
Microtubule (MT)
Amatuximab-Compound 80 linker
 ADC Info 
ADC Name Payload Target Linker ADC Info
Anetumab ravtansine
DM4
Microtubule (MT)
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
 ADC Info 
Anetumab corixetan [4]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Anetuzumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
JP7623413B2 ExampleADC52 [5]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Anti-MSLN Anti-ody Fab fragment
 Antibody Info 
ADC Name Payload Target Linker ADC Info
RG7787 [6]
Pseudomonas exotoxin PE24
Eukaryotic elongation factor 2 kinase (EEF2K)
Undisclosed
 ADC Info 
Anti-MSLN antibody
 Antibody Info 
ADC Name Payload Target Linker ADC Info
HBM9033
YL0010014
DNA topoisomerase 1 (TOP1)
VK*G-NHCH2-O linker
 ADC Info 
Anti-MSLN IgG1-ALA12
 Antibody Info 
ADC Name Payload Target Linker ADC Info
ALA12-Val-Cit-MMAE [7]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MSLN IgG1-CHS5
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CHS5-Val-Cit-MMAE [7]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MSLN IgG1-CHS7
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CHS7-Val-Cit-MMAE [7]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MSLN IgG1-CHS8
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CHS8-Val-Cit-MMAE [7]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MSLN IgG1-SS1
 Antibody Info 
ADC Name Payload Target Linker ADC Info
SS1-Val-Cit-MMAE [7]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MSLN mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Anti-MSLN-45 ADC [8]
Tetrahydroisoquinoline-based PBD dimer 17
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MSLN-46 ADC [8]
Tetrahydroisoquinoline-based PBD dimer 17
Human Deoxyribonucleic acid (hDNA)
PEG2-Val-Cit-PABC
 ADC Info 
Anti-MSLN-47 ADC [8]
Tetrahydroisoquinoline-based PBD dimer 17
Human Deoxyribonucleic acid (hDNA)
PEG4-Val-Cit-PABC
 ADC Info 
Anti-MSLN-48 ADC [8]
Tetrahydroisoquinoline-based PBD dimer 17
Human Deoxyribonucleic acid (hDNA)
PEG8-Val-Cit-PABC
 ADC Info 
Anti-MSLN-44 ADC [8]
Tetrahydroisoquinoline-based PBD dimer 14
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Cit-PABC
 ADC Info 
RC88-PY-MAA-Val-Cit-PAB-MMAE [9]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
RC88-PY-MAA-Val-Cit-PAB-MMAD [9]
Monomethyl auristatin D
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
RC88-Mc-Val-Cit-PAB-MMAE [9]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
RC88-Mc-Val-Cit-PAB-MMAD [9]
Monomethyl auristatin D
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MSLN mAb 6A4
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Anti-MSLN mAb 6A4-IIIa-01 [10]
Anti-MSLN mAb 6A4-IIIa-01 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIa-01 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIa-02 [10]
Anti-MSLN mAb 6A4-IIIa-02 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIa-02 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIa-03 [10]
Anti-MSLN mAb 6A4-IIIa-03 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIa-03 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIa-04 [10]
Anti-MSLN mAb 6A4-IIIa-04 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIa-04 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIa-05 [10]
Anti-MSLN mAb 6A4-IIIa-05 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIa-05 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIa-06 [10]
Anti-MSLN mAb 6A4-IIIa-06 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIa-06 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIa-07 [10]
Anti-MSLN mAb 6A4-IIIa-07 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIa-07 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIa-08 [10]
Anti-MSLN mAb 6A4-IIIa-08 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIa-08 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-01 [10]
Anti-MSLN mAb 6A4-IIIb-01 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-01 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-02 [10]
Anti-MSLN mAb 6A4-IIIb-02 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-02 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-03 [10]
Anti-MSLN mAb 6A4-IIIb-03 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-03 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-04 [10]
Anti-MSLN mAb 6A4-IIIb-04 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-04 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-05 [10]
Anti-MSLN mAb 6A4-IIIb-05 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-05 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-06 [10]
Anti-MSLN mAb 6A4-IIIb-06 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-06 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-07 [10]
Anti-MSLN mAb 6A4-IIIb-07 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-07 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-08 [10]
Anti-MSLN mAb 6A4-IIIb-08 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-08 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIb-09 [10]
Anti-MSLN mAb 6A4-IIIb-09 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIb-09 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIc-01 [10]
Anti-MSLN mAb 6A4-IIIc-01 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIc-01 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIc-02 [10]
Anti-MSLN mAb 6A4-IIIc-02 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIc-02 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIc-03 [10]
Anti-MSLN mAb 6A4-IIIc-03 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIc-03 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIc-04 [10]
Anti-MSLN mAb 6A4-IIIc-04 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIc-04 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIc-05 [10]
Anti-MSLN mAb 6A4-IIIc-05 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIc-05 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIc-06 [10]
Anti-MSLN mAb 6A4-IIIc-06 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIc-06 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIc-07 [10]
Anti-MSLN mAb 6A4-IIIc-07 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIc-07 linker
 ADC Info 
Anti-MSLN mAb 6A4-IIIc-08 [10]
Anti-MSLN mAb 6A4-IIIc-08 payload
Undisclosed
Anti-MSLN mAb 6A4-IIIc-08 linker
 ADC Info 
Anti-MSLN mAb 6A4-A [10]
Anti-MSLN mAb 6A4-A payload
Undisclosed
Anti-MSLN mAb 6A4 linker
 ADC Info 
Anti-MSLN scFv
 Antibody Info 
ADC Name Payload Target Linker ADC Info
LMB-100 [11]
Pseudomonas exotoxin LO10R456A
Eukaryotic elongation factor 2 kinase (EEF2K)
Undisclosed
 ADC Info 
LMB-12 [11]
Pseudomonas exotoxin PE24
Eukaryotic elongation factor 2 kinase (EEF2K)
Undisclosed
 ADC Info 
LMB-164 [11]
Pseudomonas exotoxin PE24
Eukaryotic elongation factor 2 kinase (EEF2K)
Undisclosed
 ADC Info 
BMS-986021
 Antibody Info 
ADC Name Payload Target Linker ADC Info
BMS-986148
Tubulysin
Microtubule (MT)
Mc-Val-Cit
 ADC Info 
ADC Name Payload Target Linker ADC Info
RG7600 [12]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Humanized IgG1 Anti-MSLN mAb h7D9.v3
 Antibody Info 
ADC Name Payload Target Linker ADC Info
RG-7600 [13]
Monomethyl auristatin E
Microtubule (MT)
Protease-labile valine-citrulline linker
 ADC Info 
Misitatug
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Misitatug blivedotin
Monomethyl auristatin E
Microtubule (MT)
PY-MAA-Val-Cit-PABC
 ADC Info 
ADC Name Payload Target Linker ADC Info
RC88-Py-MAA-Val-Cit-PAB-MMAE [14]
Monomethyl auristatin E
Microtubule (MT)
PY-MAA-Val-Cit-PABC
 ADC Info 
RC88-Py-MAA-Val-Cit-PAB-MMAD [14]
Monomethyl auristatin D
Undisclosed
PY-MAA-Val-Cit-PABC
 ADC Info 
RC88-Mc-Val-Cit-PAB-MMAE [14]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
RC88-Mc-Val-Cit-PAB-MMAD [14]
Monomethyl auristatin D
Undisclosed
Mc-Val-Cit-PABC
 ADC Info 
Undisclosed
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Immunoconjugate (Bayer AG)
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
NAV-001 [15]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
LCB14-17nn [16]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Anti-mesothelin antibody-drug conjugate (Bristol Myers Squibb) [17]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
MSLN ADC (Development Center for Biotechnology) [18]
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 ADC Info 
MSLN MMAE [19]
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 ADC Info 
Tubulysin-aMeso ADC (Lysine-conjugated random ADCs) [20]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Deacetyl tubulysin-aMeso ADC (Lysine-conjugated random ADCs) [20]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Hinge-cysteine ADC [20]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
N297Q ADC [20]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
CN105899515B I [21]
CN105899515B I payload
Undisclosed
Undisclosed
 ADC Info 
References
Ref 1 Antibody-drug conjugates (A2DCs) with enzymatically cleavable groups
Ref 2 MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FR Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675. doi: 10.1158/1535-7163.MCT-17-1215. Epub 2018 Sep 27.
Ref 3 Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 4 ADC review: basic information about Anetumab corixetan.
Ref 5 Antibody-drug complexes containing hemiasterlin derivatives
Ref 6 Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Res. 2016 Mar 15;76(6):1560-8. doi: 10.1158/0008-5472.CAN-15-2401. Epub 2015 Dec 30.
Ref 7 Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries. Sci Rep. 2021 Jul 29;11(1):15430. doi: 10.1038/s41598-021-94902-1.
Ref 8 Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates. J Med Chem. 2020 Nov 25;63(22):13913-13950. doi: 10.1021/acs.jmedchem.0c01385.
Ref 9 Anti-mesothelin antibody and antibody-drug conjugate thereof; 2019-11-28.
Ref 10 Benzodiazepine dimers, conjugates thereof, and methods of making and using.
Ref 11 Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1. doi: 10.1016/j.clcc.2019.06.006. Epub 2019 Jul 2.
Ref 12 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
Ref 13 Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 Mar;15(3):439-47. doi: 10.1158/1535-7163.MCT-15-0693.
Ref 14 Anti-mesothelin antibody and antibody drug conjugate thereof
Ref 15 NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects. PLoS One. 2023 May 17;18(5):e0285161. doi: 10.1371/journal.pone.0285161.
Ref 16 ADC review: basic information about LCB14-17NN.
Ref 17 Introduction to basic information on anti-mesothelin antibody-drug conjugate(Bristol Myers Squibb).
Ref 18 Anti-MSLN ADC against cancer; institute of pharmaceutics development center for biotechnology; 2020
Ref 19 A clinical candidate anti-mesothelin-MMAE antibody-drug conjugate (ADC) for therapy of mesothelin-expressing cancers. Cancer Res (2014) 74 (19_Supplement): 4494.
Ref 20 The Impact of Conjugation Mode and Site on Tubulysin Antibody-Drug-Conjugate Efficacy and Stability
Ref 21 Derivatives of uncialamycin, methods of synthesis and uses as antitumor agents